Lidoject-1 - General Information

A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]


Pharmacology of Lidoject-1

Lidoject-1 is an anesthetic agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Lidoject-1 appears to be similar to that of procaine, procainamide and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. In contrast to the latter 3 drugs, Lidoject-1 in therapeutic doses does not produce a significant decrease in arterial pressure or in cardiac contractile force. In larger doses, lidocaine may produce circulatory depression, but the magnitude of the change is less than that found with comparable doses of procainamide.


Lidoject-1 for patients

Patient may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia.

The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures.


Lidoject-1 Interactions

The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.

Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.


Lidoject-1 Contraindications

Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.


Additional information about Lidoject-1

Lidoject-1 Indication: For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
Mechanism Of Action: Lidoject-1 stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Lidocaine
Synonyms: Dilocaine; L-Caine
Drug Category: Antiarrhythmic Agents; Anesthetics
Drug Type: Small Molecule; Approved

Other Brand Names containing Lidocaine: Dalcaine; Lidoject-1; Lidoject-2; Octocaine; Xylocaine; Xylocaine-MPF; Xylocaine-MPF with Glucose; Octocaine-50; Octocaine-100; Xylocaine Test Dose; Xylocaine 5% Spinal; After Burn Double Strength Gel; After Burn Double Strength Spray; After Burn Gel; After Burn Spray; Alphacaine; Anestacon; Anestacon Jelly; Cappicaine; DermaFlex; Duncaine; Emla; Esracaine; Gravocain; Isicaina; Lanabiotic; Leostesin; Lidoderm; Lignocaine; Maricaine; Norwood Sunburn Spray; Rocephin Kit; Xylocaine Dental Ointment; Xylocaine Endotracheal; Xylocaine Viscous; Xylocard; Zilactin-L; Solarcaine; Solarcaine aloe extra burn relief cream; Solcain; Zingo;
Absorption: Information derived from diverse formulations, concentrations and usages reveals that lidocaine is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.
Toxicity (Overdose): The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Protein Binding: 60-80%
Biotransformation: Primarily hepatic.
Half Life: 109 minutes
Dosage Forms of Lidoject-1: Solution Intravenous
Liquid Topical
Liquid Intravenous
Ointment Topical
Spray Topical
Lotion Topical
Solution Oral
Liquid Buccal
Cream Topical
Gel Topical
Aerosol Topical
Swab Topical
Jelly Topical
Liquid Dental
Solution Intramuscular
Liquid Oral
Solution Topical
Jelly Urethral
Aerosol, metered Topical
Liquid Infiltration
Solution Infiltration
Chemical IUPAC Name: 2-diethylamino-N-(2,6-dimethylphenyl)acetamide
Chemical Formula: C14H22N2O
Lidocaine on Wikipedia:
Organisms Affected: Humans and other mammals